N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Sponsor: Climb Bio, Inc. • ClinicalTrials.gov ID: NCT07564596

Registry updated: 2026-10-20
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b/2a, open-label study will evaluate budoprutug in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE, where pharmacodynamics will be evaluated as the change in the number of B cells and immunoglobulins (antibodies) in the blood over time. Budoprutug will be administered as two (2) IV infusions 14 days apart in ascending dose cohorts.

Interventions

  • Budoprutug (Drug)
    Single IV dose of study product on Day 1 and Day 15

Eligibility criteria

Inclusion Criteria: 1. Aged 18 to 65 years at the time of consent. 2. Diagnosis of SLE according to the 2019 European League Against. Rheumatism and the American College of Rheumatology (ACR) classification criteria. 3. Active, seropositive disease, with SLEDAI 2K \>=6 at screening 4. Inadequate response to at least one therapeutic intervention Exclusion Criteria: 1. Active neuropsychiatric SLE. 2. Active lupus nephritis type III or IV that is expected to require induction therapy during the study or recently treated with induction therapy within 12 weeks. 3. Prior diagnosis of, or fulfills diagnostic criteria for, other autoimmune or inflammatory disease that may confound clinical assessments or increase subject risk in the study 4. Active systemic infection or history of chronic, recurrent, latent, or recent serious infections.

Conditions

Systemic Lupus Erthematosus

Locations

  • Mianyang Central Hospital — Mianyang, Sichuan, China
  • Baoji Central Hospital — Baoji, China
  • Peking University People's Hospital — Beijing, China
  • The First Affiliated Hospital of Bengbu Medical College — Bengbu, China
  • Xiangya Second Hospital of Central South University — Changsha, China
  • The First Affiliated Hospital of the University of Science — Hefei, China
  • The First Affiliated Hospital of Nanchang — Nanchang, China
  • The Second Affiliated Hospital of Soochow University — Suzhou, China
  • Shanxi Bethune Hospital — Taiyuan, China
  • Zaozhuang Municipal Hospital — Zaozhuang, China
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record